Hu-Mik-Beta-1 / National Institute of Neurological Disorders and Stroke - LARVOL DELTA

Antibody Treatment for Advanced Celiac Disease (clinicaltrials.gov) - P1; N=5; Completed; Sponsor: National Cancer Institute (NCI); Recruiting ➔ Completed; N=12 ➔ 5; Trial completion date: Jun 2021 ➔ Dec 2019; Trial primary completion date: Jun 2020 ➔ Dec 2019

Clinical • Enrollment change • Trial completion • Trial completion date • Trial primary completion date

Hu Mik-Beta-1 to Treat HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (clinicaltrials.gov) - P1; N=9; Completed; Sponsor: National Institute of Neurological Disorders and Stroke (NINDS); Trial completion date: Oct 2017 ➔ Jun 2019

Trial completion date

Hu-Mik-beta1 to Treat T-Cell Large Granular Lymphocytic Leukemia (clinicaltrials.gov) - P1; N=9; Completed; Sponsor: National Cancer Institute (NCI); Trial completion date: Nov 2010 ➔ Jan 2019

Clinical • Trial completion date